Impact of baseline C-reactive protein on the efficacy and safety of rivaroxaban monotherapy in atrial fibrillation and stable coronary artery disease: a post-hoc AFIRE analysis
Event: ESC Congress 2025
Topic: Secondary Prevention
Session: Secondary prevention: biomarkers to optimise outcomes
